Literature DB >> 9139208

[Problems in diagnosis and therapy of malignant pleural mesothelioma].

A Türler1, S P Mönig, M Raab.   

Abstract

The incidence of malignant pleural mesothelioma increased continuously during recent years. This is related to widespread use and processing of asbestos in the last decades. Characteristical symptoms like dyspnea, cough and thoracic pain are common in almost all pulmonal diseases. Therefore the possible occurrence of a pleural tumor is often neglected. This leads to a delay between onset of symptoms and the establishment of diagnosis. With X-ray and computed tomography 80% of the pleural tumors can be proved. Only in few cases the histopathological analysis of the pleural fluid leads to diagnosis. However, thoracoscopy or thoracotomy remain the most reliable means of obtaining a definitive tissue diagnosis. At the time of operation advanced stages are found in many cases, therefore palliative surgery is indicated. Due to high morbidity and mortality pleuropneumonectomy should be done only in selected patients. Pleurectomy or pleurodesis is often sufficient to release patients' symptoms. Chemotherapy and radiation have not proven effective in controlling malignant mesothelioma. In conclusion pleural mesothelioma remains a tumor with a very poor prognosis. Long term survival is occasional even in case of multimodal treatment.

Entities:  

Mesh:

Year:  1997        PMID: 9139208     DOI: 10.1007/bf03042291

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  36 in total

1.  Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma.

Authors:  D J Sugarbaker; E C Heher; T H Lee; G Couper; S Mentzer; J M Corson; J J Collins; R Shemin; R Pugatch; L Weissman
Journal:  J Thorac Cardiovasc Surg       Date:  1991-07       Impact factor: 5.209

2.  The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.

Authors:  V W Rusch; S Piantadosi; E C Holmes
Journal:  J Thorac Cardiovasc Surg       Date:  1991-07       Impact factor: 5.209

3.  Multimodality therapy for malignant mesothelioma based on a study of natural history.

Authors:  K H Antman; R H Blum; J S Greenberger; G Flowerdew; A T Skarin; G P Canellos
Journal:  Am J Med       Date:  1980-03       Impact factor: 4.965

4.  [Malignant pleural mesothelioma: diagnosis, therapy and prognosis].

Authors:  S Geroulanos; P Lampe; F Häfner; P Buchmann; F Largiadèr
Journal:  Schweiz Rundsch Med Prax       Date:  1990-03-20

5.  [Malignant pleural mesothelioma. Value of 67Ga scintigraphy compared to computerized tomography].

Authors:  K U Wentz; G Irngartinger; P Georgi; G van Kaick; M Kleckow; H H Vollhaber
Journal:  Rofo       Date:  1986-07

6.  Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group.

Authors:  F J van Breukelen; K Mattson; G Giaccone; N van Zandwijk; H T Planteydt; A Kirkpatrick; O Dalesio
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

7.  Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma.

Authors:  V W Rusch
Journal:  Chest       Date:  1993-04       Impact factor: 9.410

8.  A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study.

Authors:  B L Zidar; B Metch; S P Balcerzak; H I Pierce; L Militello; M D Keppen; J L Berenberg
Journal:  Cancer       Date:  1992-11-15       Impact factor: 6.860

9.  Multimodality treatment programs for malignant pleural mesothelioma using high-dose hemithorax irradiation.

Authors:  K Mattson; L R Holsti; L Tammilehto; P Maasilta; S Pyrhönen; M Mäntylä; M Kajanti; U S Salminen; J Rautonen; L Kivisaari
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

10.  [Carcinoembryonic antigen in serum and pleural fluid to distinguish between bronchial carcinoma and pleural mesothelioma].

Authors:  J Mezger; R Lamerz; M Bresgen; A Schulz; K H Berghäuser; F Liewald; L Sunder-Plassmann; K Häussinger; W Wilmanns
Journal:  Dtsch Med Wochenschr       Date:  1991-02-08       Impact factor: 0.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.